SEK 15m · Other round · Healthtech · Stockholm, Sweden
Eyedentity, a Stockholm healthtech company building AI-assisted diagnostics for serious eye diseases, has raised SEK 15m in its first investment round. Norrsken Launcher led the oversubscribed financing, with Karolinska Institutet Innovation and angel investors also participating. The company will use the capital to pursue regulatory approval, develop further diagnostic capabilities and prepare the platform for wider use across opticians, eye clinics and hospitals.
Existing eye exams become the distribution channel
Eyedentity's first application targets uveal melanoma, a rare eye cancer that can be difficult to distinguish from benign conditions at an early stage. Rather than introduce a separate screening visit or new imaging device, the company is designing its software to analyse fundus images already captured during routine eye examinations. It is testing the technology with Synologen, a network of independent Swedish opticians.
That workflow is commercially important. Opticians already see people who may not have entered specialist eye care, so software that flags concerning images could extend the reach of early detection without asking customers to build a new acquisition channel. It could also make the referral decision more selective: the product is intended to identify cases that warrant specialist assessment while reducing avoidable referrals into a capacity-constrained system. Those benefits remain company and investor claims until regulatory and clinical evidence supports routine use.
The financing therefore buys more than product development. Eyedentity needs to turn a live pilot into evidence for regulatory approval, integrate its decision support into everyday optical workflows and show that clinicians can act consistently on its output. Each step is linked: accuracy alone will not create adoption if the software produces too many unnecessary referrals, while a smooth workflow will not compensate for insufficient clinical validation.
The company plans to expand beyond uveal melanoma into diabetic retinopathy, glaucoma and other eye diseases. A multi-condition platform could spread integration costs across more use cases and make the software more valuable to optical networks. But the first product is the proof point. Regulatory clearance, pilot results and dependable referral pathways will determine whether the same infrastructure can support additional conditions rather than remaining a single-disease tool.
Sources checked:
Karolinska Institutet Innovation · EU-Startups · Eyedentity · Tech.eu Funding Explorer
